Genentech is committed to discovering and developing innovative medicines for metabolic diseases. We focus on creating new treatment options for patients with diabetes to manage their disease and avoid its complications.
While new medications for glucose control have been developed in recent years, none of the available medications affects the steady deterioration in pancreatic function that is characteristic of type 2 diabetes. The loss of physiologic glucose control as pancreatic function declines mean that diabetic retinopathy and nephropathy are significant and growing health problems that we seek to address.
We partnered on a survey that identified a significant gap in the understanding of diabetes and vision loss. Learn more.